Navigation Links
Xenon Receives BIOTECanada Gold Leaf Award
Date:6/17/2008

VANCOUVER, British Columbia, June 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has been awarded the Promising Early Stage Company of the Year Award by BIOTECanada in the Health category for 2008.

"We are delighted to have received this prestigious award, one of BIOTECanada's four Gold Leaf Awards presented this year," commented Simon Pimstone, Xenon's President and CEO. "This honor is important and made even more so by the fact that it represents recognition by our industry peers of both our achievements to date and the potential that Xenon offers."

"Xenon has made substantial progress in advancing its pipeline of novel compounds acting against targets derived from our clinical genetics approach. In the next 12 months we should have multiple products in clinical development for potential blockbuster markets. Our product pipeline is diverse, and we are excited to be advancing our discoveries into clinical opportunities," Pimstone added.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in pain, lipid modification for treating diabetes/obesity and other diseases, as well as therapies for treating anemia and diseases of iron overload. Xenon has partnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical Company Ltd. For more information, visit the Company's website at http://www.xenon-pharma.com


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Xenon Announces Appointment of VP, Discovery Research
2. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
3. Advance Nanotechs Owlstone Subsidiary Receives Order From IEE
4. Met-Pro Corporations Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000
5. CryoLifes BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery
6. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
7. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
8. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
9. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
10. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
11. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for TenoMend(TM) Collagen Tendon Wrap for the Management and Protection of Tendon Injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):